A Look At IDEAYA Biosciences (IDYA) Valuation After New DLL3 Combo Trial Progress And Early Responses [Yahoo! Finance]
IDEAYA Biosciences, Inc. (IDYA)
Last ideaya biosciences, inc. earnings: 3/24 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
IDEAYA Biosciences (IDYA) is back in focus after reporting the first patient has been treated in a Phase 1 trial that combines IDE849 and IDE161 in DLL3 upregulated solid tumors, including small cell lung cancer and melanoma. See our latest analysis for IDEAYA Biosciences. The recent trial update comes after a period where short term share price returns have been mixed, with a 7 day share price return of 2.03% and a 30 day share price return decline of 4.58%, while the 1 year total shareholder return of 110.28% and 3 year total shareholder return of 131.21% point to strong longer term momentum. If this kind of oncology catalyst interests you, it can be useful to scan for other healthcare names using AI to drive progress, including 37 healthcare AI stocks With IDEAYA generating revenue of US$218.71 million but still reporting a net loss of US$113.70 million, and the shares trading at US$32.74 versus a US$50.00 analyst target, is there still a buying opportunity here, or is the
Show less
Read more
Impact Snapshot
Event Time:
IDYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IDYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IDYA alerts
High impacting IDEAYA Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
IDYA
News
- IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer [Yahoo! Finance]Yahoo! Finance
- IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer [TheStreet.com]TheStreet.com
- IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung CancerPR Newswire
- Why IDEAYA Biosciences (IDYA) Is Up 7.5% After Early Data From First-in-Class Cancer Combo [Yahoo! Finance]Yahoo! Finance
- IDEAYA Biosciences (IDYA) had its "outperform" rating reaffirmed by Wedbush. They now have a $52.00 price target on the stock.MarketBeat
IDYA
Earnings
- 2/17/26 - Beat
IDYA
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/2/26 - Form 4
- 2/17/26 - Form S-8
- IDYA's page on the SEC website